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Background: The use of immunotherapy for cancer is increasing and is expected to continue growing. The out
comes after solid organ transplantation(SOT) in patients who received immunotherapy before SOT remain un
clear. We evaluated the global transplant surgery community’s attitude towards and experience with patients
who received immunotherapy for malignancy before SOT.
Methods: An online-based survey was sent to North American transplant program directors in December-2020
and members of the International Liver Transplant Society in November-2021 evaluating experiences with
and attitudes towards SOT in recipients with previous immunotherapy for cancer.
Results: A total of 119 respondents completed the survey(119/175;completion rate:68%), representing centers
from North America, South America, Europe, Asia, and Australia. Seventy-one(62%) respondents would consider
SOT in patients with a previous history of immunotherapy for cancer, whereas thirty-nine(34%) were aware of
such immunotherapy-treated recipients being transplanted, with an increasing trend over the last few years(2016
[n = 1]-2020[n = 14]). Institutional clinical management policies in this setting were lacking in most centers(n
= 85[75%]).
Conclusions: The international transplant community is receptive to transplanting transplant candidates previ
ously treated with immunotherapy for cancer, although experience is still limited. In this context, more centers
have started to offer SOT to patients with a history of immunotherapy for cancer in recent years. However,
support from clear and robust institutional policies in this endeavor is scant. Therefore, there is a high need for
consensus guidelines to inform future clinical management, especially as immunotherapy for cancer is likely to
continue to increase in the coming years.

1. Introduction
The use of immunotherapy for cancer is increasing and is expected to
continue to grow [1,2]. Outcomes after solid organ transplantation
(SOT), specifically the risk of post-transplant rejection, remain unclear

in patients who have received pre-transplant immunotherapy for cancer
indications.
The use of checkpoint inhibitors has been associated with a high
allograft rejection rate and mortality in the posttransplant setting [3].
Regarding the pretransplant setting, nivolumab and toripalimab as a
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bridging therapy for hepatocellular carcinoma (HCC) has been associ
ated with fatal hepatic necrosis after liver transplant [4,5]. In contrast,
another recent case with pretransplant use of nivolumab had a favorable
outcome post-liver transplant without tumor recurrence or graft rejec
tion at a follow-up of one year [2]. In the former case, the last dose of
nivolumab was given eight days before transplantation, whereas in the
latter case, 15 weeks elapsed before the last dose of nivolumab and the
transplant. This suggests that the time between immunotherapy and
SOT may be relevant. Nonetheless, no guidelines exist for managing
transplant candidates and recipients who have received immunotherapy
for cancer indications before listing SOT. Within this context, whether
these patients should be offered transplant listing and, if so, what con
stitutes an optimal duration between immunotherapy and transplant
remains to be determined. Moreover, the global transplant community’s
experience with this clinical scenario is unknown, but is likely limited.
Consequently, there is suspected heterogeneity in transplant practice,
making understanding what constitutes optimal management of patients
who have received previous immunotherapy for cancer and who could
subsequently benefit from an SOT challenging.
Therefore, this study aimed to explore the contemporary global
transplant surgery community’s attitude towards and experience with
patients who have received immunotherapy for cancer before SOT.

2. Methods
This study is an international multicenter survey that was distributed
to program directors of North American transplant centers through the
American Society of Transplantation (AST) Liver and Intestinal Com
munity of Practice (LICOP) Education Subcommittee and members of
the International Liver Transplant Society (ILTS). A 31-question survey
was developed to query transplant program directors regarding their
experience with and attitudes towards SOT in patients with previous
cancer immunotherapy (Supplementary material). The information
from survey respondents was collected using an online survey distrib
uted through REDCap via email to 113 program directors beginning on
3-December 2020. This was followed by two reminder emails at bimonthly intervals. Additionally, members of the International Liver
Transplant Society (ILTS) were contacted in November-2021 in a similar
fashion. The study was closed on 20-December 2021. All the re
spondents’ survey responses were identified (Fig. 1).
2.1. Objectives
The primary objective of the survey was to explore the experience of
transplant centers globally with respect to SOT following immuno
therapy for malignancies. The secondary objectives are as follows:

Fig. 1. STROBE-compliant diagram of respondent inclusion and exclusion for the survey.
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1. Evaluation of the attitudes of transplant centers globally towards
SOT following immunotherapy treatment for malignancies.
2. An assessment of how many individuals may have been denied a
transplant because of prior exposure to immunotherapy.
3. A description of the immunotherapy regimens used in patients who
underwent transplantation.
4. An estimation of the average post-transplantation outcomes in pa
tients who received prior immunotherapy for malignancy with re
gard to rejection episodes, graft and patient survival.
5. An evaluation of center interest in performing a subsequent multiinstitutional retrospective study to evaluate this clinical situation.

Table 1
Baseline information.
Overall (N =
175)
Country
Afghanistan
Argentina
Australia
Austria
Azerbaijan
Belgium
Brazil
Chile
China
Costa Rica
Ecuador
France
Germany
India
Italy
Japan
South Korea
Mexico
Netherlands
Norway
Philippines
Poland
Singapore
Spain
Switzerland
Taiwan
Turkey
United Kingdom
United States
Uruguay
Annual liver transplant volume
Median (Q1, Q3)
Annual kidney transplant volume
Median (Q1, Q3)
Annual pancreas transplant volume
Median (Q1, Q3)
Annual heart transplant volume
Median (Q1, Q3)
Annual lung transplant volume
Median (Q1, Q3)
1a. Would you consider offering an organ transplant to a
patient with a previous history of immunotherapy
treatment for cancer?
N-Missing
Maybe/Don’t know
No
Yes
2a. Are you aware of any transplant recipients at your
institution that were denied listing for transplantation
based on prior immunotherapy exposure?
N-Missing
Don’t recall
No
Yes
3a. Are you aware of any transplant recipient in your
institution that received immunotherapy for cancer before
an organ transplant?
N-Missing
Don’t recall
No
Yes
4a. Does your transplant program have any policies in place
regarding clinical management of these patients?
N-Missing
Don’t know
No
Yes
5a. Would you be interested in compiling a case series to study
the results of organ transplantation in patients who
received immunotherapy before transplantation?
N-Missing

Before distribution, the survey proposal was discussed at the AST
LICOP Meeting of 16-March 2020 and approved for distribution to the
liver and intestinal directors of programs in the United States. Similarly,
the ILTS approved the distribution of the survey on 27-October 2021.
Additional approval by the Institutional Research Ethics Board (REB) of
the University Health Network (UHN) was obtained (REB#20–5464).
All respondents were required to provide informed consent to partici
pate in the survey.
2.1.1. Study population
Qualified physicians hold the role of director of a North American
transplant program or member of the ILTS.
2.1.2. Survey
The survey was administered by REDCap, a secure online data cap
ture application supported by the UHN infrastructure. A generic link to
the REDCap survey was emailed to the transplant center programme
directors and members of the ILTS. The email content explained that the
recipients were invited to participate in the study. The exact content
language is appended in a document entitled “letter of intent”. Consent
to participate in the study was obtained prior to proceeding. Consent
and survey information are included in the Supplementary Information
(Supplementary Material). The survey instrument is provided as sup
plementary material (Supplementary Material). All the survey re
spondents were anonymous.
2.2. Statistical analysis
Descriptive data are expressed as the median and interquartile range
(IQR). Categorical variables were expressed as numbers and percentages
(%). Statistical analyses were performed using R version 4.1.1 (R Core
Team (2021). R: A language and environment for statistical computing.
R Foundation for Statistical Computing, Vienna, Austria. http://www.
R-project.org/).
3. Results

3.1.1. Survey responses and program demographics
One hundred and nineteen of the 175 respondents completed the
survey for a completion rate of 68% (i.e., 175 respondents accessed the
survey and consented to participate, but only 119 responded to subse
quent questions) (Fig. 1). Respondents represented centers from North
America, South America, Europe, Asia, and Australia. Most represented
centers were from the United States (n = 27 [30%]), followed by India
(n = 10 [11%]), and Italy (n = 7 [8%]) (Table 1).
3.1.2. Annual transplant volumes
Respondents reported the number of annual transplants performed at
their center for various organs as follows: median (IQR), liver 65
(38–111), kidney 75 (30–192), pancreas 2 (0− 10), heart 3 (0–24), and
lung 0 (0− 11) (Table 1).

1 (1%)
3 (3%)
1 (1%)
2 (2%)
1 (1%)
1 (1%)
2 (2%)
1 (1%)
1 (1%)
2 (2%)
1 (1%)
1 (1%)
1 (1%)
10 (11%)
7 (8%)
2 (2%)
1 (1%)
2 (2%)
1 (1%)
1 (1%)
1 (1%)
1 (1%)
3 (3%)
5 (6%)
1 (1%)
1 (1%)
4 (4%)
3 (3%)
27 (30%)
2 (2%)
65 (38, 111)
75 (30, 192)
2 (0,10)
3 (0, 24)
0 (0,11)

61
29 (25%)
14 (12%)
71 (62%)

61
15 (13%)
87 (76%)
12 (11%)

61
9 (8%)
66 (58%)
39 (34%)
62
4 (4%)
85 (75%)
24 (21%)

65
33 (30%)

(continued on next page)
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Table 1 (continued )

Table 2
Immunotherapy for cancer before transplantation.

Overall (N =
175)
Maybe/Don’t know/Need to determine feasibility of
participation
No
Yes

Time-frame between treatment and transplant – If “yes” to 1a.
Would you consider offering an organ transplant to a patient with a
previous history of immunotherapy treatment for cancer?

6 (6%)
71 (65%)

1b. What would you consider an acceptable time-frame between the
treatment and transplant?
<4 months
4–12 months
12–24 months
>24 months
Number of denied listings - If “yes” to 2a. Are you aware of any
transplant recipients at your institution that were denied listing
for transplantation based on prior immunotherapy exposure?
2b. How many such patients are you aware of at your institution?
1–2
3–5
>5
Transplant recipients with prior immunotherapy – If “yes” to 3a.
Are you aware of any transplant recipient in your institution that
received immunotherapy for cancer before an organ transplant?
3b. How many patients are you aware of at your institution received
immunotherapy for cancer before an organ transplant?
1–2
3–5
>5
3c. Approximately when did you transplant your first patient who
had received prior immunotherapy for cancer?
Missing
Earlier
2016
2017
2018
2019
2020
3d. In the patients that received an organ transplant after
immunotherapy receipt for cancer - what was the
immunotherapy treatment for?
Missing
Don’t recall
Liver cancer
Hematological
Melanoma
Other
3e. What type of immunotherapy was used
Missing
Don’t recall
Immune checkpoint inhibitor
Immune system modulator
Monoclonal antibody
T-cell transfer therapy
3f. For how many months was the immunotherapy used?
Missing
Don’t know
<6 months
6–12 months
12–24 months
>24 months
3g. Were these treatments a single dose, multiple doses, or full
regimen?
Missing
Don’t know
Full regimen
Single
Multiple
3h. What was the approximate time period between the last dose of
immunotherapy and transplant?
Missing
Don’t know
<6 months
6–12 months
12–24 months
>24 months
3i. Did any of these patients experience any episodes of acute
rejection after transplant?
Missing
Don’t recall

3.1.3. Attitudes and experience
Fourteen (12%) respondents would not consider offering an organ
transplant to a patient with a previous history of immunotherapy
treatment for cancer whereas twenty-nine (25%) responded maybe/do
not know. Seventy-one (62%) respondents considered offering an organ
transplant to such a patient (Table 1), and of these, thirty-nine (55%)
considered an acceptable time frame between the treatment and trans
plant as 4–12 months (Table 2).
Twelve (11%) respondents were aware of transplant recipients at
their institution who were denied listing for transplantation based on
prior immunotherapy exposure (Table 1). Of these, seven (58%) recalled
1–2 patients, four (33%) recalled 3–5 patients, and one (8%) recalled
more than 5 patients denied listing for transplantation (Table 2). Thirtynine (34%) respondents were aware of transplant recipients in their
institution who received immunotherapy for cancer before an SOT,
whereas 66 (58%) did not (Table 1). Of the respondents who were aware
of transplant recipients, twenty-six (67%) were aware of 1–2 patients,
five (13%) of 3–5 patients and eight (21%) of >5 patients. There was a
progressively increasing trend in the number of patients respondents
were aware of having been transplanted with prior immunotherapy
receipt for cancer over time (before 2016, n = 2 [5%], 2016 n = 1 [3%],
2017 n = 1 [3%], 2018 n = 9 [24%], 2019 n = 10 [26%], and 2020 n =
14 [37%]) (Table 2).
3.1.4. Policies
Twenty-four (21%) respondents reported that their transplant pro
gram had policies regarding the clinical management of these patients,
whereas eighty-five (75%) did not (Table 1). Of the twenty-four with
policies in place, 20 (83%) reported that their institution required a
certain time period between the last dose of immunotherapy and SOT.
Thirteen (54%) respondents reported required <6 months, two (8%)
6–12 months, three (13%) 12–24 months, and two (8%) required >24
months (Table 2).
3.1.5. Pre-transplant immunotherapy cancer treatment in patients who then
underwent SOT
Immune checkpoint inhibitors were the most frequently used
immunotherapy (n = 29 [76%]). The duration of immunotherapy was
<6 months (n = 11 [29%]), 6–12 months (n = 11 [29%]), 12–24 months
(n = 4 [11%]), >24 months (n = 1 [3%]), and do not know/do not recall
(n = 11 [29%]) (Table 2). The immunotherapy treatment regimens were
single-dose (n = 3 [8%]), multiple-dose (n = 27 [71%]), full regimen (n
= 3 [8%]), and do not know/do not recall (n = 5 [13%]). The approx
imate time periods between the last dose of immunotherapy and trans
plant were < 6 months (n = 20 [53%]), 6–12 months (n = 13 [34%]),
12–24 months (n = 1 [3%]), >24 months (n = 3 [8%]), and do not
know/do not recall (n = 1 [3%]) (Table 2).
3.1.6. Post-transplant
3.1.6.1. Rejection. Of the respondents who were aware of transplant
recipients with previous immunotherapy receipt for cancer at their
institution, ten (26%) reported these recipients experiencing any epi
sodes of acute rejection (Table 2). Twenty-four (63%) responded no,
four (11%) did not recall, and there was one missing response. In pa
tients who experienced rejection, the approximate period of rejection
was <1 month (n = 7 [70%]), 1–3 months (n = 1 [10%]), >3 months (n

Overall (N =
71)

17 (24%)
39 (55%)
7 (10%)
8 (11%)
Overall (N =
12)
7 (58%)
4 (33%)
1 (8%)
Overall (N =
39)
26 (67%)
5 (13%)
8 (21%)
1
2 (5%)
1 (3%)
1 (3%)
9 (24%)
10 (26%)
14 (37%)

1
1 (3%)
30 (79%)
3 (8%)
1 (3%)
3 (8%)
1
2 (5%)
29 (76%)
2 (5%)
4 (11%)
1 (3%)
1
11 (29%)
11 (29%)
11 (29%)
4 (11%)
1 (3%)
1
5 (13%)
3 (8%)
3 (8%)
27 (71%)
1
1 (3%)
20 (53%)
13 (34%)
1 (3%)
3 (8%)
1
4 (11%)

(continued on next page)
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contributing causes of death in patients who died included malignancy
(n = 3 [43%]) and rejection (n = 4 [57%]) (Table 2). In comparison with
an average transplant patient, respondents felt that the patient survival
in these patients was the same (n = 18 [47%]), worse (n = 3 [8%]), or
had not followed them for enough time to make the determination (n =
16 [42%]) (Table 2).

Table 2 (continued )
Time-frame between treatment and transplant – If “yes” to 1a.
Would you consider offering an organ transplant to a patient with a
previous history of immunotherapy treatment for cancer?

Overall (N =
71)

No
Yes
3j. Did any of the transplanted patients die (for any reason)?
Missing
Don’t recall/Don’t know
No
Yes
3k. Graft survival: In your opinion and experience, how do the
outcomes of these patients compare to the average transplant
patient?
Missing
Have not followed them for enough time to make this
determination
Better
Same
Worse
3l. Patient survival: In your opinion and experience, how do the
outcomes of these patients compare to the average transplant
patient?
Missing
Have not followed them for enough time to make this
determination
Better
Same
Worse
Time-period between immunotherapy and transplant - If “yes” to
4a. Does your transplant program have any policies in place
regarding clinical management of these patients
4b. Do you require a certain time period between last dose of
immunotherapy and transplant?
No
Yes, <6 months
Yes, 6–12 months
Yes, 12–24 months
Yes, >24 months
Acute rejection after transplant - If “yes” to 3i. Did any of these
patients experience any episodes of acute rejection after
transplant?
3i.S1 What was the approximate period of rejection if there was a
rejection?
Don’t know/Don’t recall
<1 month
1–3 months
>3 months
3i.S2 Estimate how many of these patients lost their grafts/died
because of severe rejection?
Don’t know/Don’t recall
1–3
3–5
Contributing cause of death - If “yes” to 3j. Did any of the
transplanted patients die (for any reason)?
3j. S1 What were the contributing causes of death?
Malignancy
Rejection

24 (63%)
10 (26%)
1
4 (11%)
27 (71%)
7 (18%)

4. Discussion
This study provides preliminary insights into the attitudes towards
and experiences with SOT after immunotherapy for cancer. Over half of
the respondents (62%) considered offering an organ transplant to a
patient with a previous history of immunotherapy for cancer. More than
one-third (34%) were aware of recipients receiving immunotherapy for
cancer before organ transplantation. Moreover, some patients are being
denied listing transplantation based on prior immunotherapy exposure.
Over the last few years, there has been an increasing trend in the number
of transplant recipients who were aware of who received immuno
therapy for cancer before their transplant. Lastly, the majority (75%) of
respondents reported an absence of institutional policies for the clinical
management of these patients. Taken together, this study highlights that
this represents a clinical scenario for which outcomes should be further
clarified, and that consensus guidelines are necessary to inform future
clinical management in these patients, especially as immunotherapy for
cancer is likely to increase in the coming years.
Most of the immunotherapy used in cancer has been for advanced or
metastatic disease [6]. However, there is likely to be an increased use in
the neoadjuvant and curative-intent setting in the future, with ongoing
studies in non-small cell lung cancer, bladder cancer, hepatocellular
carcinoma (HCC), melanoma, head and neck squamous cell cancer,
breast cancer, esophageal cancer, gastroesophageal cancer, pancreatic
cancer, colorectal cancer, and sarcoma. Cancer immunotherapy has
been studied in the post-transplant setting, where the indications have
been mostly for metastatic melanoma or HCC [6,7]. In this setting, Miao
et al. found that the use of mTOR and calcineurin inhibitors may help to
reduce the occurrence of host-versus-graft response, one of the feared
complications of immunotherapy in both the pre- and post-transplant
settings [5,7]. Such information may be helpful for the development
of guidelines for patients who have received cancer immunotherapy in
the pre-transplant setting.
The optimal timeframe between cancer immunotherapy exposure
and solid organ transplantation remains to be clarified and may be in
part guided by the half-life of the agent used. Within this context, the
target occupancy of PD-1 persists significantly longer than the half-life
of the drug. In the case of nivolumab, PD-1 saturation was found on
circulating lymphocytes for up to 100 days after a single 10-ml/kg dose,
despite the half-life at that dose being 27-days [8–10]. Rejection rep
resents a major concern in the transplant setting after previous immu
notherapy and warrants further investigation. In the context of our
survey, the 7 respondents who reported any death in their transplanted
patients, rejection was the contributing cause in 4 (57%). Nordness et al.
described a case of fatal hepatic necrosis when the timeframe between
nivolumab cessation and the transplant was eight days [4]. In contrast,
Schwacha-Eipper et al. reported no organ rejection when the timeframe
was six weeks [2]. Schnickel et al. recently reported their single-center
experience with pre-liver transplant use of nivolumab in five patients
[11]. None of their patients who underwent liver transplant beyond
three months from the last dose of nivolumab experienced biopsyproven acute cellular rejection [11].
Liver cancer was the most common indication for immunotherapy
receipt among the respondents who reported experience with organ
transplant after immunotherapy receipt for cancer, and the most com
mon type of immunotherapy used was an immune checkpoint inhibitor.
Tabrizian et al. recently reported the largest single-institution series
(nine patients) of patients who received anti-programmed cell death
protein 1/programmed death ligand 1 (PD-1/PD-L1) checkpoint

1
14 (37%)
1 (3%)
21 (55%)
2 (5%)

1
16 (42%)
1 (3%)
18 (47%)
3 (8%)
Overall (N =
24)

4 (17%)
13 (54%)
2 (8%)
3 (13%)
2 (8%)
Overall (N =
10)

1 (10%)
7 (70%)
1 (10%)
1 (10%)
3 (30%)
6 (60%)
1 (10%)
Overall (N =
7)
3 (43%)
4 (57%)

= 1 [10%]), and did not know or do not recall (n = 1 [10%]) (Table 2).
On estimation of how many of these patients lost their grafts or died
because of severe rejection, six (60%) responded 1–3, one (10%) 3–5,
none (0%) >5, and three (30%) did not know or did not recall (Table 2).
There was no statistically significant difference between rejection
occurrence and the different time durations between the last dose of
immunotherapy and transplant (p = 0.35). In comparison with an
average transplant patient, respondents felt that the graft survival in
these patients was the same (n = 21 [55%]), worse (n = 2 [5%]), or had
not followed them for enough time to make the determination (n = 14
[37%]) (Table 2).
3.1.6.2. Death. The respondents were aware of such patients dying (for
any reason) in seven (18%), whereas twenty-seven (71%) reported no,
and four (11%) could not recall or did not know (Table 2). The
5
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inhibitor for HCC before liver transplant between 2017 and 2020 [12].
In this series, 89% (n = 8) received their last dose of nivolumab within
four weeks of transplantation [12]. The group reported no allograft re
jections, graft losses, tumor recurrences, or post-transplant deaths at a
median follow-up of 16 months (range 8–23) [12]. After noting that
liver transplantation can be performed safely if at least three months
have elapsed since final checkpoint inhibitor treatment, Schnickel et al.
have altered their peritransplant protocol based on their recent case
series to include a 3-month waiting period before transplant [11].
Moreover, they also screen for donor-specific antibodies and thymo
globulin induction after having observed high levels of DSA that per
sisted despite plasmapheresis and rituximab treatment in one of their
early patients [11]. The reason for this is speculated to be due to the PD1 expression of B cells, resulting in increased antibody production after
checkpoint inhibitor therapy [13]. Though these results can be inter
preted with cautious optimism, it offers early insight that trans
plantation may be feasible in select circumstances after previous
immunotherapy receipt for cancer.

necessary to develop clinical practice guidelines and improve patient
outcomes, particularly because immunotherapy for cancer is likely to
increase in the coming years.
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